U.S., March 18 -- ClinicalTrials.gov registry received information related to the study (NCT06880029) titled 'Circadian Rhythm Impact on TNBC Response to Neoadjuvant Immunotherapy' on March 11.
Brief Summary: CIRCADIAN is a prospective randomized clinical trial designed to evaluate the impact of pembrolizumab infusions' time-of-day on pathological complete response (pCR) rate among TNBC patients undergoing neoadjuvant treatment.
Study Start Date: Sept. 01, 2024
Study Type: INTERVENTIONAL
Condition:
Triple Negative Breast Cancer (TNBC)
Intervention:
OTHER: Morning pembrolizumab infusions
Patients will be randomized 1:1 to receive all three neoadjuvant pembrolizumab cycles in the morning (before noon) or in the afternoon (after noon)....